ArticleScientific reports2017
Insulin-like Growth Factor 1 in relation to future hearing impairment: findings from the English Longitudinal Study of Ageing.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- [Research progress on the protective mechanism of insulin like growth factor-1 on inner ear].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2021Pooled it
- IGF-1/SLC25A33 Maintains Blood-Labyrinth Barrier Integrity by Suppressing TGF-β/Smad2-Mediated Pericyte Activation in Age-Related Hearing Loss.Aging cell · 2026Article
- Risk of audiologic side effects with teprotumumab treatment for thyroid eye disease: propensity matched analysis.Eye (London, England) · 2025Article
- Advances in the Study of Etiology and Molecular Mechanisms of Sensorineural Hearing Loss.Cell biochemistry and biophysics · 2024Review
- Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.International journal of clinical pharmacy · 2024Article
- Teprotumumab-Related Hyperglycemia.The Journal of clinical endocrinology and metabolism · 2023Observational
- Allostatic load and risk of hearing impairment.Brain, behavior, & immunity - health · 2022Article
- Subjective Aging and Objectively Assessed Hearing Function: A Prospective Study of Older Adults.The journals of gerontology. Series B, Psychological sciences and social sciences · 2022Article
- Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease.The Journal of clinical endocrinology and metabolism · 2022Review
- Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.American journal of ophthalmology · 2022Observational
- Neuroprotective role of insulin-like growth factor 1 in auditory and other nervous systems.Histology and histopathology · 2022Review
- Sense of Purpose in Life and Markers of Hearing Function: Replicated Associations across Two Longitudinal Cohorts.Gerontology · 2022Article
- Hyperbaric Oxygen Therapy Promotes Hearing Gain with Increases in Serum IGF-1 and HSP70 in Patients with Idiopathic Sudden Sensorineural Hearing Loss.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Translational implications of the interactions between hormones and age-related hearing loss.Hearing research · 2021Review
- Gender Modifies the Association of Cognition With Age-Related Hearing Impairment in the Health and Retirement Study.Frontiers in public health · 2021Article
- Association of inflammatory markers with hearing impairment: The English Longitudinal Study of Ageing.Brain, behavior, and immunity · 2020Article
- Neuroprotective factors and incident hearing impairment in the epidemiology of hearing loss study.The Laryngoscope · 2019Article
- Longitudinal associations between hearing loss and general cognitive ability: The Lothian Birth Cohort 1936.Psychology and aging · 2019Article
- Pregnancy-associated plasma protein-aa supports hair cell survival by regulating mitochondrial function.eLife · 2019Article
- The Role of Insulin-Like Growth Factor 1 in the Progression of Age-Related Hearing Loss.Frontiers in aging neuroscience · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Insulin-like Growth Factor 1 (IGF-1) is associated with cardiovascular disease, itself a risk factor for hearing impairment, and, in animal studies, molecular evidence suggests a role for IGF-1 in hearing function. However, the link between IGF-1 and the occurrence of hearing impairment is untested in population-based studies of humans. A total of 4390 participants aged ≥50 y (mean [SD] age 64.2 [8.0] years at baseline, 55% women) from the English Longitudinal Study of Ageing provided serum levels of IGF-1 in 2008 and again in 2012. Hearing acuity was assessed by an objective hearing test (HearCheck handheld device) in 2014 when the prevalence was 38.2%. In the full cohort, IGF-1 was not associated with subsequent hearing impairment (OR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.